Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Regeneron Pharmaceuticals Inc : Regeneron Pharmaceuticals Assigned Patent

12/31/2013 | 03:06am US/Eastern

By Targeted News Service

ALEXANDRIA, Va., Dec. 31 -- Regeneron Pharmaceuticals, Tarrytown, N.Y., has been assigned a patent (8,613,927) developed by five co-inventors for a "high affinity human antibodies to human nerve growth factor." The co-inventors are Lynn MacDonald, White Plains, N.Y., Richard Torres, New York, Marc R. Morra, Beacon Falls, Conn., Joel H. Martin, Putnam Valley, N.Y., and Joel C. Reinhardt, Mount Kisco, N.Y.

The patent application was filed on Feb. 28, 2012 (13/406,734). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=3&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=141&f=G&l=50&co1=AND&d=PTXT&s1=20131224.PD.&s2=%28NY.ASST.%29&OS=ISD/12/24/2013+AND+AS/NY&RS=ISD/12/24/2013+AND+AS/NY

Written by Sudarshan Harpal; edited by Jaya Anand.

SH1231JA1231-963857

© Targeted News Service, Acquiremedia 2014
Latest news on REGENERON PHARMACEUTICALS
2d ago REGENERON PHARMACEUTICALS : Assigned Patent
3d ago REGENERON PHARMACEUTICALS : Ranked Number One Biopharmaceutical Employer by Scie..
3d ago REGENERON PHARMACEUTICALS : Reports on Vaccines from Regeneron Pharmaceuticals I..
3d ago REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Demonstrates Significan..
4d ago SANOFI : and Regeneron Announce Start of Phase 3 Study of Dupilumab in Patients ..
4d ago REGENERON PHARMACEUTICALS : Earns Top Spot as Employer in the Global Biopharmace..
5d ago REGENERON PHARMACEUTICALS : and Sanofi Announce Start of Phase 3 Study of Dupilu..
6d ago REGENERON PHARMACEUTICALS : FDA OKs Eylea (aflibercept) Injection
10/17 REGENERON PHARMACEUTICALS : S&P 500 Analyst Moves: REGN
10/17DJAmgen Files Patent Infringement Suit Over Cholesterol Drug
Advertisement
Chart
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF